Katherine Y Ebright

Title: Katherine Y Ebright: Innovator in Antibacterial Drug Discovery

Introduction

Katherine Y Ebright is a prominent inventor based in New Brunswick, NJ (US). She has made significant contributions to the field of antibacterial drug discovery. Her innovative work focuses on targeting bacterial RNA polymerase, which is crucial for developing new antibacterial compounds.

Latest Patents

Katherine holds a patent for her invention titled "Bridge-helix cap: target and method for inhibition of bacterial RNA polymerase." This patent highlights the discovery of the Sal target, which represents a promising avenue for antibacterial drug development. The Sal target is distinct from existing targets, such as rifamycin and CBR703, indicating that compounds targeting Sal may have minimal cross-resistance with these drugs. This discovery opens the door for co-administration of antibacterial compounds, potentially leading to additive or synergistic effects while suppressing the emergence of resistance.

Career Highlights

Katherine is affiliated with Rutgers, the State University of New Jersey, where she conducts her research. Her work has garnered attention for its potential impact on public health and the fight against antibiotic resistance. With her innovative approach, she is paving the way for new treatments that could save lives.

Collaborations

Katherine collaborates with notable colleagues, including Richard H Ebright and David Degen. Their combined expertise enhances the research efforts in the field of antibacterial drug discovery.

Conclusion

Katherine Y Ebright is a trailblazer in the realm of antibacterial research, with her innovative patent offering new hope in the fight against bacterial infections. Her contributions are vital in addressing the growing challenge of antibiotic resistance.